Method of Treating or Ameliorating Type 1 Diabetes Using FGF21
AssigneeAmgen Inc.
InventorsMurielle Marie Ellison, Shanaka Stanislaus, Jing Xu
Life of this patent
Estimating the term…
Abstract
Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease
Claims30
A method of treating a metabolic disorder comprising administering to a subject in need thereof a therapeutically effective amount of (a) an isolated human FGF21 polypeptide;
- or (b) an FGF21 variant polypeptide.
A method of treating a metabolic disorder comprising administering to a subject in need thereof a therapeutically effective amount of a human FGF21 polypeptide comprising an amino acid sequence that has at least 90% sequence identity with one of SEQ ID NOs:4 and 8.
Dependencies are inferred from the claim text.